The American Journal of Managed Care

LAMA-LABA Therapy Provides Improved Outcomes in COPD Over ICS-LABA

The findings provide further support of recommendations in the clinical guidelines to favor one therapy over the other. Patients with chronic obstructive pulmonary disease (COPD) being treated with ...
Healio

Medium-dose inhaled corticosteroid plus LABA best for pediatric uncontrolled asthma

Please provide your email address to receive an email when new articles are posted on . Moving from a low-dose inhaled corticosteroid to a medium-dose inhaled corticosteroid plus a long-acting beta ...
The American Journal of Managed Care

Implementing Inhaled Corticosteroids (ICS) into COPD Patient Treatment Regimen

Inhaled corticosteroids (ICSs) are a key incorporation to COPD treatment strategies. Jeffrey D. Dunn, PharmD, MBA: ICSs [inhaled corticosteroids] haven’t shown much evidence in impacting the course of ...
Nature

Inappropriate prescribing of combination inhalers in Northern Ireland: retrospective cross-sectional cohort study of prescribing practice in primary care

Asthma management guidelines advocate a stepwise approach to asthma therapy, including the addition of a long-acting bronchodilator to inhaled steroid therapy at step 3. This is almost exclusively ...
Medscape

Inhaled Beta2-agonist Initiation and Risk of Cardiovascular Events

In patients with chronic obstructive pulmonary disease (COPD), new initiation of beta2-agonist therapy, such as short-acting beta2-agonists (SABA), long-acting beta2-agonists (LABA), or inhaled ...
Healio

Fluticasone-based ICS, LABA therapy changes airway microbiome in COPD

Please provide your email address to receive an email when new articles are posted on . Fluticasone-based inhaled corticosteroid treatment substantially changed airway microbiome diversity in patients ...
Medscape

New Inhaled Therapies for COPD

We have had 2 long-acting ICS/LABA combinations for several years: a fluticasone/salmeterol combination (Advair®) and a formoterol/budesonide combination (Symbicort ...
FiercePharma

GSK's Advair ® Diskus® achieves primary endpoint in LABA safety study of patients with asthma

GlaxoSmithKline plc (GSK) today announced results from the 'LABA' (long acting beta 2-agonist) safety study, AUSTRI(SAS115359). The study compared Advair ® Diskus ®, a combination of the LABA, ...
MedPage Today

COPD Inhalers' Link to Fracture Risk Supported in Pooled Trials

Chronic obstructive pulmonary disease (COPD) treatments involving inhaled corticosteroids (ICSs) were associated with a greater risk for fractures, a meta-analysis of several dozen randomized trials ...
Science Daily

Certain risk factors can predict the risk for COPD exacerbations in patients using inhaled medications

Gastroesophageal reflux disease (GERD), being female, and certain scores on the St. George’s Respiratory Questionnaire (SGRQ) were associated with exacerbations of chronic obstructive pulmonary ...
FiercePharma

NEJM publishes results of GSK's long-term LABA safety study of Advair ® Diskus® in adults and adolescents with asthma

GlaxoSmithKline plc (LSE/NYSE:GSK) today announced publication of results from the 'LABA' (long acting beta2-agonist) safety study, AUSTRI (SAS115359) in the New England Journal of Medicine (NEJM).